Literature DB >> 30685562

Chronic itch management: therapies beyond those targeting the immune system.

Emilie Fowler1, Gil Yosipovitch2.   

Abstract

OBJECTIVE: Chronic itch can be a debilitating, unrelenting symptom. Over the years, we have advanced our knowledge about immune-mediated itch (eg, atopic dermatitis) and have developed several treatments targeting these immune pathways. Chronic itch that is noninflammatory in nature is more elusive. However, we have gained some understanding of the neural component mediating itch and have made progress in treating this challenging symptom. DATA SOURCES: A comprehensive literature search was conducted, and data and literature were reviewed on the topics of chronic itch, its pathophysiology, and nonimmunological treatments for chronic itch that work on the nerves. STUDY SELECTIONS: Basic science papers, review articles, case reports, and clinical trial data were considered.
RESULTS: A variety of topical and systemic therapies targeting the nerves have shown effectiveness in treating patients with chronic itch of different types.
CONCLUSION: Treating chronic itch may be challenging, but an arsenal of treatments are available and many are on the horizon as we expand our knowledge of mechanisms of itch and the neural receptors involved.
Copyright © 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30685562     DOI: 10.1016/j.anai.2019.01.016

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  9 in total

1.  Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Authors:  Saadet Inan; Alvaro Torres-Huerta; Liselotte E Jensen; Nae J Dun; Alan Cowan
Journal:  Eur J Pharmacol       Date:  2019-09-27       Impact factor: 4.432

2.  Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch.

Authors:  Johannes Wohlrab; David Stintzing; Luise Schultz; Konstantin Jügelt; Olaf H-U Schroeder
Journal:  Skin Pharmacol Physiol       Date:  2021-09-16       Impact factor: 3.479

Review 3.  Pruritus in Keloid Scars: Mechanisms and Treatments.

Authors:  Ahmed A Hawash; Giuseppe Ingrasci; Keyvan Nouri; Gil Yosipovitch
Journal:  Acta Derm Venereol       Date:  2021-10-28       Impact factor: 3.875

Review 4.  Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch.

Authors:  Shirin Kahremany; Lukas Hofmann; Arie Gruzman; Guy Cohen
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

Review 5.  The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients.

Authors:  Alessandro Allegra; Eleonora Di Salvo; Marco Casciaro; Caterina Musolino; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Biomedicines       Date:  2020-12-22

Review 6.  Clinical management of chronic kidney disease-associated pruritus: current treatment options and future approaches.

Authors:  Zoe M Lipman; Vijayakumar Paramasivam; Gil Yosipovitch; Michael J Germain
Journal:  Clin Kidney J       Date:  2021-10-14

7.  Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications.

Authors:  Sarina Elmariah; Sarah Chisolm; Thomas Sciascia; Shawn G Kwatra
Journal:  JAAD Int       Date:  2022-04-20

Review 8.  A New Generation of Treatments for Itch.

Authors:  Emilie Fowler; Gil Yosipovitch
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

Review 9.  Management of Itch in the Elderly: A Review.

Authors:  Kayla M Fourzali; Gil Yosipovitch
Journal:  Dermatol Ther (Heidelb)       Date:  2019-09-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.